C
Ceptaris Therapeutics
Pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides
About Ceptaris Therapeutics
Ceptaris Therapeutics, Inc. was a specialty pharmaceutical company founded in 2002 and formerly known as Yaupon Therapeutics. The company focused on developing and commercializing treatments for dermatological and central nervous system diseases.
The company's primary asset was VALCHLOR® (mechlorethamine) gel, a proprietary formulation developed for the topical treatment of early-stage mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma. Prior to VALCHLOR, patients depended on non-standardized, pharmacy-compounded preparations of mechlorethamine. Ceptaris's product was developed to provide a standardized, FDA-reviewed treatment option. VALCHLOR is an alkylating drug applied once daily as a thin film to affected skin areas, designed to inhibit the proliferation of cancer cells.
The company's business model was centered on obtaining regulatory approval for VALCHLOR and then commercializing it for specialists in dermatology and oncology. A significant milestone was achieved in August 2013, when the U.S. Food and Drug Administration (FDA) granted marketing approval for VALCHLOR for Stage IA and IB mycosis fungoides-type CTCL in patients who have received prior skin-directed therapy. This approval was a pivotal event for the company, following a previous Complete Response Letter from the FDA which had requested additional information.
In July 2013, anticipating the drug's approval, Swiss biopharmaceutical company Actelion Ltd entered into an agreement to acquire Ceptaris. The acquisition was contingent on the FDA's approval of VALCHLOR. The deal involved an upfront payment of $25 million, with an additional $225 million paid to Ceptaris' shareholders upon the transaction's closing in September 2013, following the FDA's green light. The agreement also included potential future payments based on sales and commercial milestones. The acquisition allowed Actelion to enter the oncology market and leverage its expertise in rare diseases to commercialize VALCHLOR.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Ceptaris Therapeutics is 0 monthly website visits. Ceptaris Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ceptaris Therapeutics in the Malvern ecosystem
The Ceptaris Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Ben Franklin Technology Partners of Southeastern Pennsylvania
BioAdvance
Series B and later7 investors entered at this stage
- PIPalo Alto Investors
Oxford Finance
Silicon Valley Bank
Burrill- APAperture Venture Partners
Third Point Ventures
Vivo Capital
Other known investors4 additional known investors
Actelion Pharmaceuticals
Aperture Ventures Partners
Mid-Atlantic Angel Group
Project Liberty Digital Incubator
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ceptaris Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ceptaris Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










